Company intelligence / Profile preview

Novit

New York, United States

Ownership: Private
Development stage: Other

Overview

Novita Pharmaceuticals has completed Phase 1 trials showing their lead fascin inhibitor NP-G2-044 is well tolerated and signals anti-tumor activity. Ongoing Phase 2A trials are evaluating efficacy as monotherapy and in combination with anti-PD-1 agents at 15 U.S. cancer centers[1][2].

Therapeutic areas: Oncology
Modalities: Small moleculeAntibody
Industry: Biotech

Partnerships

Collaborations with multiple U.S. cancer centers (15 sites for Phase 2A trial)

Beyond the preview

Go deeper on Novit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novit.

Explore the full profile